Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
commercially available in creams and serums at concentrations of 1-3% Subcutaneous injection : Research doses typically 100-200 mcg administered locally Iontophoresis : Electrical delivery through skin has been studied for enhanced penetration Microneedling combination : Topical application combined with microneedling for deeper delivery The topical availability of GHK-Cu makes it significantly more accessible than BPC-157 for surface-level applications
The safety profile of both peptides is generally favorable in the available research
diagnostic evaluation history Careful review of medication list, focusing on any recent changes (look up drugs individually to determine if they lower seizure threshold, or if they participate in drug-drug interactions with other medications that affect seizure threshold)
No published trial preclinical or human has tested the combination
In other words, smaller daily doses are better than infrequent higher ones
These are favorable odds for a relatively low-risk intervention, but they underscore that peptide therapy does not work for everyone
